Revolution Medicines, Inc.
NASDAQRevolution Medicines enters September with the analyst re-rating from last week holding firm — and the short position that greeted those upgrades continuing to shrink, even as the stock has given back a fraction of its gains. The Street's conviction has only grown since the August 27 wave of target hikes. Needham raised its target to $275 on August 31, and UBS followed with a lift…
RVMD put/call ratio collapses to 0.52, four standard deviations below the 20-day average of 0.76—the most bullish options positioning in over a year.
Revolution Medicines enters September with the analyst re-rating from last week holding firm — and the short position that greeted those upgrades continuing to shrink, even as the stock has given back a fraction of its…
Six analyst firms raised their price targets on Revolution Medicines on Wednesday alone. That wall of upgrades is the defining story here — and the rest of the data is moving in the same direction. Oppenheimer, RBC…
Snapshot as of 20 Sept 2026
Revolution Medicines is trading near $211 with shorts unwinding and options turning sharply more bullish — yet the CEO just sold over $15 million of stock at the highs, creating a pointed divergence that defines the…
Revolution Medicines just delivered a week where the stock and the Street moved in the same direction at the same time — a relatively rare alignment that has the options market taking notice in its own telling way. The…
Revolution Medicines is trading at $190.46 — up 28% over the past month and now within touching distance of the Street's mean price target — creating a fresh question about whether the re-rating has run its course or…
Revolution Medicines enters July with an unusually clear alignment between analyst conviction and options sentiment — both shifting decisively in the bulls' favour even as insiders quietly lock in gains. The most…
Revolution Medicines heads into its June 18 Q1 results with the Street's conviction rising and short sellers quietly rebuilding positions after a month of covering. The analyst story is the dominant theme this week.…
Revolution Medicines reports Q1 2026 results today having become one of the most striking momentum stories in biotech this year. The stock closed at $151.07, up 52% over the past month and 7.5% on the week alone — a…
Revolution Medicines heads into its Q1 2026 earnings release with a rare alignment: a landmark clinical publication, a collapsing short position, and a Wall Street analyst community that has spent two weeks racing to…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RVMD — free to start on ORTEX.
Sign up for free →Open RVMD on ORTEX